CSL Limited (ASX: CSL): Share Price Update and Horizon 2 Manufacturing Trial Progress

Aditi Sarkar

30 July 2026 01:34 AM AEST

CSL Limited (ASX: CSL): Share Price Update and Horizon 2 Manufacturing Trial Progress

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CSL shares recorded a modest change in the latest ASX trading session.
The company outlined plans for clinical trials linked to a next-generation manufacturing process.
The initiative involves engagement with international regulatory authorities.
The stock has recorded a marked decline over the past twelve months.

CSL Limited (ASX: CSL) closed the 30 July 2026 (AEST) session at A$127.93 per share, down A$0.14, or 0.11%, from the previous close. Trading volume for the session reached 1,425,642 shares, with the company's market capitalisation recorded at A$61.3 billion.

Over the past twelve months, CSL shares have moved by approximately -52.81%, based on the referenced closing price data. This figure is presented for descriptive context alongside the day's more modest movement.

Recent Corporate Development: Horizon 2 Plasma Manufacturing Update

On 29 July 2026, CSL announced plans to begin clinical trials for immunoglobulin produced using its next-generation Horizon 2 manufacturing process, with clinical activities expected to commence in mid-2027.

Horizon 2 is described as a patented, yield-enhancing technology designed to increase immunoglobulin production from the same amount of plasma input, which the company indicated could support manufacturing efficiency over time.

CSL confirmed it is working with the United States Food and Drug Administration and European regulatory authorities to generate the clinical evidence required to support future regulatory approvals for the Horizon 2 process. Clinical trial material is set to be produced at CSL's Broadmeadows facility, with the trials running alongside a previously announced expansion of the company's Kankakee, Illinois manufacturing facility.

About CSL Limited

CSL Limited is a biotechnology company listed on the Australian Securities Exchange, with core operations in plasma-derived therapies and related manufacturing processes. Given the nature of its industry, CSL's share price can be influenced by factors including clinical trial outcomes, regulatory decisions, manufacturing developments, and broader trends within the healthcare and biotechnology sector.

Understanding Manufacturing and Clinical Trial Updates

Updates on manufacturing technology and associated clinical trials, such as the Horizon 2 announcement, provide insight into a company's longer-term operational and regulatory pathway. Clinical trials are typically conducted over an extended period and are subject to regulatory oversight before any associated process or product can be approved for broader use. As such, an announcement of planned trial commencement reflects an early stage in a longer development timeline, rather than a confirmed operational or commercial outcome.

Conclusion

CSL Limited's 30 July 2026 close reflected a modest decline for the session, occurring within the context of a more pronounced decline over the past twelve months. The company's recent update on its Horizon 2 manufacturing process and associated clinical trial plans adds a further dimension to the available information on CSL's ongoing activities. Readers are encouraged to refer to CSL's official announcements for complete details, and this article is intended for educational purposes only and does not constitute financial advice.

FAQs

Q: What was CSL's share price at the close on 30 July 2026?

A:CSL Limited (ASX: CSL) closed at A$127.93 per share, down A$0.14, or 0.11%, for the session.

Q: What is Horizon 2?

A:Horizon 2 is a patented, yield-enhancing manufacturing process designed to increase immunoglobulin production from the same amount of plasma.

Q: When are Horizon 2 clinical trials expected to begin?

A:CSL indicated that clinical activities are expected to commence in mid-2027.

Q: What is CSL's current market capitalisation?

A:As at the 30 July 2026 close, CSL's market capitalisation was recorded at A$61.3 billion.

Q: How has CSL shares performed over the past year?

A:Based on available closing price data, CSL shares have moved by approximately -52.81% over the trailing twelve-month period.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.